We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CXM:NYSESprinklr, Inc. Analysis

Data as of 2026-03-28 - not real-time

$5.88

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Sprinklr, Inc. delivered a solid Q4 performance with revenue up 9% YoY to $220.6M and an earnings beat that prompted a $125M accelerated share repurchase, underscoring strong cash generation (free cash flow $142.5M). Technical signals are mixed: the stock trades below its 20‑day (5.89) and 50‑day (5.98) SMAs, indicating a bearish price trend, yet the MACD histogram is positive and the MACD signal is bullish, while volume is on an increasing trajectory. The price sits near a key support level of $5.59 and faces resistance around $6.20, with a 30‑day volatility of 44% and a beta of ~1.03, suggesting heightened short‑term risk. Fundamentally, the company trades at a trailing PE of 65× versus an industry average of 32×, but a forward PE of 10.9× and a DCF‑derived fair value of $12.94 imply a potential upside of roughly 44% from the current $5.88 price. Management issued cautious FY27 guidance amid macro‑uncertainty, tempering enthusiasm despite the growth narrative. Overall, the stock appears undervalued on a discounted cash‑flow basis, but investors must navigate the near‑term bearish bias and elevated volatility.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat and share repurchase support price stability
  • Price below short‑term moving averages indicating bearish bias
  • High volatility and proximity to support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward PE compression to 10.9× suggesting earnings acceleration
  • DCF upside of ~44% and growing free cash flow
  • Increasing trading volume and bullish MACD signal

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Expanding AI‑driven SaaS platform addressing large enterprise TAM
  • Strong balance sheet with low debt and ample cash
  • Undervaluation relative to DCF and industry growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth8.90%
Profit Margin2.67%
P/E Ratio65.3
ROE3.80%
ROA2.98%
Debt/Equity7.88
P/B Ratio2.5
Op. Cash Flow$159.2M
Free Cash Flow$142.5M
Industry P/E32.0

Technical Analysis

TrendBearish
RSI49.0
Support$5.59
Resistance$6.20
MA 20$5.89
MA 50$5.98
MA 200$7.50
MACDBullish
VolumeIncreasing
Fear & Greed Index65.98

Valuation

Fair Value$12.94
Target Price$8.50
Upside/Downside44.56%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.03
Volatility44.11%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.